Effects of minocycline on Fas-mediated fulminant hepatitis in mice

British Journal of Pharmacology

Volumn 144, Issue 2, 2005, Pages 275-282

  Chu, Heng Cheng ^a,b   Lin, Yi Ling ^c   Sytwu, Huey Kang ^d   Lin, Shin Hua ^d   Liao, Ching Len ^d,e   Chao, You Chen ^b,f  

^a Postgrad Inst of Medical Science   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e Yeong An Clinic Orthopaedics and Rehabilitation   (Taiwan)

^f NONE   (Taiwan)

Author keywords

Caspase; Cytochrome c; Fas; Fulminant hepatitis; Minocycline; Mitochondria

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; FAS ANTIBODY; FAS ANTIGEN; JO2 ANTIBODY; LIVER EXTRACT; MINOCYCLINE; PROTEIN BID; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVATION; ENZYME RELEASE; HEPATITIS; HISTOPATHOLOGY; KINETICS; LIVER MITOCHONDRION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 13444273017     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706079     Document Type: Article

References (48)

1. AMIN, A.R., ATTUR, M.G., THAKKER, G.D., PATEL, P.D., VYAS, P.R., PATEL, R.N., PATEL, I.R. & ABRAMSON, S.B. (1996). A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl. Acad. Sci. U.S.A., 93, 14014-14019.
2. ASHKENAZI, A. & DIXIT, V.M. (1998). Death receptors: signaling and modulation. Science, 281, 1305-1308.
3. ATILLASOY, E. & BERK, P.D. (1995). Fulminant hepatic failure: pathophysiology, treatment, and survival. Annu. Rev. Med., 46, 181-191.
4. BAJT, M.L., LAWSON, J.A., VONDERFECHT, S.L., GUJRAL, J.S. & JAESCHKE, H. (2000). Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor in vivo: evidence for a postmitochondrial processing of caspase-8. Toxicol. Sci., 58, 109-117.
5. BOCKER, R., ESTLER, C.J. & LUDEWIG-SANDIG, D. (1991). Evaluation of the hepatotoxic potential of minocycline. Antimicrob. Agents Chemother., 35, 1434-1436.
6. CHANG, B., NISHIKAWA, M., SATO, E. & INOUE, M. (2003). Mice lacking inducible nitric oxide synthase show strong resistance to anti-Fas antibody-induced fulminant hepatitis. Arch. Biochem. Biophys., 411, 63-72.
7. CHEN, M., ONA, V.O., LI, M., FERRANTE, R.J., FINK, K.B., ZHU, S., BIAN, J., GUO, L., FARRELL, L.A., HERSCH, S.M., HOBBS, W., VONSATTEL, J.P., CHA, J.H. & FRIEDLANDER, R.M. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 6, 797-801.
8. DU, Y., MA, Z., LIN, S., DODEL, R.C., GAO, F., BALES, K.R., TRIARHOU, L.C., CHERNET, E., PERRY, K.W., NELSON, D.L., LUECKE, S., PHEBUS, L.A., BYMASTER, F.P. & PAUL, S.M. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A., 98, 14669-14674.
9. FELDMANN, G., HAOUZI, D., MOREAU, A., DURAND-SCHNEIDER, A.M., BRINGUIER, A., BERSON, A., MANSOURI, A., FAU, D. & PESSAYRE, D. (2000). Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology, 31, 674-683.
10. GALLE, P.R., HOFMANN, W.J., WALCZAK, H., SCHALLER, H., OTTO, G., STREMMEL, W., KRAMMER, P.H. & RUNKEL, L. (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med., 182, 1223-1230.
11. GOLUB, L.M., GOODSON, J.M., LEE, H.M., VIDAL, A.M., MCNAMARA, T.F. & RAMAMURTHY, N.S. (1985). Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems. J. Periodontol., 56, 93-97.
12. GOUGH, A., CHAPMAN, S., WAGSTAFF, K., EMERY, P. & ELIAS, E. (1996). Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ, 312, 169-172.
13. GREEN, D.R. & REED, J.C. (1998). Mitochondria and apoptosis. Science, 281, 1309-1312.
14. KLEIN, N.C. & CUNHA, B.A. (1995). Tetracyclines. Med. Clin. N. Am., 79, 789-801.
15. LACRONIQUE, V., MIGNON, A., FABRE, M., VIOLLET, B., ROUQUET, N., MOLINA, T., PORTEU, A., HENRION, A., BOUSCARY, D., VARLET, P., JOULIN, V. & KAHN, A. (1996). Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med., 2, 80-86.
16. LAWRENSON, R.A., SEAMAN, H.E., SUNDSTROM, A., WILLIAMS, T.J. & FARMER, R.D. (2000). Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf., 23, 333-349.
17. LI, H., ZHU, H., XU, C.J. & YUAN, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501.
18. LIN, S., WEI, X., XU, Y., YAN, C., DODEL, R., ZHANG, Y., LIU, J., KLAUNIG, J.E., FARLOW, M. & DU, Y. (2003). Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci., 72, 1635-1641.
19. LI, P., NIJHAWAN, D., BUDIHARDJO, I., SRINIVASULA, S.M., AHMAD, M., ALNEMRI, E.S. & WANG, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91, 479-489.
20. LUO, X., BUDIHARDJO, I., ZOU, H., SLAUGHTER, C. & WANG, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94, 481-490.
21. MALASSAGNE, B., FERRET, P.J., HAMMOUD, R., TULLIEZ, M., BEDDA, S., TREBEDEN, H., JAFFRAY, P., CALMUS, Y., WEILL, B. & BATTEUX, F. (2001). The superoxide dismutase mimetic MnTBAP prevents Fas-induced acute liver failure in the mouse. Gastroenterology, 121, 1451-1459.
22. MALCOLM, A., HEAP, T.R., ECKSTEIN, R.P. & LUNZER, M.R. (1996). Minocycline-induced liver injury. Am. J. Gastroenterol., 91, 1641-1643.
23. MIYACHI, Y., YOSHIOKA, A., IMAMURA, S. & NIWA, Y. (1986). Effect of antibiotics on the generation of reactive oxygen species. J. Invest. Dermatol., 86, 449-453.
24. OGASAWARA, J., WATANABE-FUKUNAGA, R., ADACHI, M., MATSUZAWA, A., KASUGAI, T., KITAMURA, Y., ITOH, N., SUDA, T. & NAGATA, S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature, 364, 806-809.
25. OKAMOTO, T. (2000). The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. Eur. J. Pharmacol., 387, 229-232.
26. OKAMOTO, T., HITOMI, Y. & HARA, A. (1999). The protective effect of cyclosporine A on anti-Fas antibody-induced hepatitis in mice. Jpn. J. Pharmacol., 79, 485-488.
27. OKAMOTO, T., KAWASAKI, T. & HINO, O. (2003). Osthole prevents anti-Fas antibody-induced hepatitis in mice by affecting the caspase-3-mediated apoptotic pathway. Biochem. Pharmacol., 65, 677-681.
28. OKAMOTO, T. & OKABE, S. (2000). Inhibition of anti-Fas antibody-induced hepatitis by aminoguanidine in mice. Eur. J. Pharmacol., 403, 277-280.
29. PETER, M.E. & KRAMMER, P.H. (1998). Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol., 10, 545-551.
30. RODRIGUEZ, I., MATSUURA, K., KHATIB, K., REED, J.C., NAGATA, S. & VASSALLI, P. (1996a). A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med., 183, 1031-1036.
31. RODRIGUEZ, I., MATSUURA, K., ODY, C., NAGATA, S. & VASSALLI, P. (1996b). Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med., 184, 2067-2072.
32. SADOWSKI, T. & STEINMEYER, J. (2001). Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J. Rheumatol., 28, 336-340.
33. SANCHEZ MEJIA, R.O., ONA, V.O., LI, M. & FRIEDLANDER, R.M. (2001). Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery, 48, 1393-1399 discussion 1399-1401.
34. SCAFFIDI, C., FULDA, S., SRINIVASAN, A., FRIESEN, C., LI, F., TOMASELLI, K.J., DEBATIN, K.M., KRAMMER, P.H. & PETER, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17, 1675-1687.
35. SCAFFIDI, C., SCHMITZ, I., ZHA, J., KORSMEYER, S.J., KRAMMER, P.H. & PETER, M.E. (1999). Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 274, 22532-22538.
36. SEINO, K., SETOGUCHI, Y., OGINO, T., KAYAGAKI, N., AKIBA, H., NAKANO, H., TANIGUCHI, H., TAKADA, Y., YUZAWA, K., TODOROKI, T., FUKUCHI, Y., YAGITA, H., OKUMURA, K. & FUKAO, K. (2001). Protection against Fas-mediated and tumor necrosis factor receptor 1-mediated liver injury by blockade of FADD without loss of nuclear factor-kappaB activation. Ann. Surg., 234, 681-688.
37. SONG, E., LEE, S.K., WANG, J., INCE, N., OUYANG, N., MIN, J., CHEN, J., SHANKAR, P. & LIEBERMAN, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 9, 347-351.
38. STRAND, S., HOFMANN, W.J., GRAMBIHLER, A., HUG, H., VOLKMANN, M., OTTO, G., WESCH, H., MARIANI, S.M., HACK, V., STREMMEL, W., KRAMMER, P.H. & GALLE, P.R. (1998). Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat. Med., 4, 588-593.
39. TILLEY, B.C., ALARCON, G.S., HEYSE, S.P., TRENTHAM, D.E., NEUNER, R., KAPLAN, D.A., CLEGG, D.O., LEISEN, J.C., BUCKLEY, L., COOPER, S.M., DUNCAN, H., PILLEMER, S.R., TUTTLEMAN, M. & FOWLER, S.E. (1995). Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann. Intern. Med., 122, 81-89.
40. WOO, M., HAKEM, A., ELIA, A.J., HAKEM, R., DUNCAN, G.S., PATTERSON, B.J. & MAK, T.W. (1999). In vivo evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes. J. Immunol., 163, 4909-4916.
41. YAMAMOTO, M., MIURA, N., OHTAKE, N., AMAGAYA, S., ISHIGE, A., SASAKI, H., KOMATSU, Y., FUKUDA, K., ITO, T. & TERASAWA, K. (2000). Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice. Gastroenterology, 118, 380-389.
42. YIN, X.M., WANG, K., GROSS, A., ZHAO, Y., ZINKEL, S., KLOCKE, B., ROTH, K.A. & KORSMEYER, S.J. (1999). Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature, 400, 886-891.
43. YRJANHEIKKI, J., KEINANEN, R., PELLIKKA, M., HOKFELT, T. & KOISTINAHO, J. (1998). Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U.S.A., 95, 15769-15774.
44. YRJANHEIKKI, J., TIKKA, T., KEINANEN, R., GOLDSTEINS, G., CHAN, P.H. & KOISTINAHO, J. (1999). A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U.S.A., 96, 13496-13500.
45. ZENDER, L., HUTKER, S., LIEDTKE, C., TILLMANN, H.L., ZENDER, S., MUNDT, B., WALTEMATHE, M., GOSLING, T., FLEMMING, P., MALEK, N.P., TRAUTWEIN, C., MANNS, M.P., KUHNEL, F. & KUBICKA, S. (2003). Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U.S.A., 100, 7797-7802.
46. ZHANG, H., COOK, J., NICKEL, J., YU, R., STECKER, K., MYERS, K. & DEAN, N.M. (2000). Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol., 18, 862-867.
47. ZHANG, H., TAYLOR, J., LUTHER, D., JOHNSTON, J., MURRAY, S., WYATT, J.R., WATT, A.T., KOO, S., YORK-DEFALCO, C., STECKER, K. & DEAN, N.M. (2003). Antisense oligonucleotide inhibition of Bcl-xL and Bid expression in liver regulates responses in a mouse model of Fas-induced fulminant hepatitis. J. Pharmacol. Exp. Ther., 31, 31.
48. ZHU, S., STAVROVSKAYA, I.G., DROZDA, M., KIM, B.Y., ONA, V., LI, M., SARANG, S., LIU, A.S., HARTLEY, D.M., WU DU, C., GULLANS, S., FERRANTE, R.J., PRZEDBORSKI, S., KRISTAL, B.S. & FRIEDLANDER, R.M. (2002). Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 417, 74-78.